

Ingrid E C Verhaart

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1124333/publications.pdf>

Version: 2024-02-01

23
papers

1,114
citations

686830

13
h-index

610482

24
g-index

24
all docs

24
docs citations

24
times ranked

1715
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy – a literature review. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 124.	1.2	391
2	Therapeutic developments for Duchenne muscular dystrophy. <i>Nature Reviews Neurology</i> , 2019, 15, 373-386.	4.9	265
3	A multi-source approach to determine SMA incidence and research ready population. <i>Journal of Neurology</i> , 2017, 264, 1465-1473.	1.8	98
4	Low dystrophin levels in heart can delay heart failure in mdx mice. <i>Journal of Molecular and Cellular Cardiology</i> , 2014, 69, 17-23.	0.9	47
5	Circulating specific antibodies enhance systemic cross-priming by delivery of complexed antigen to dendritic cells in vivo. <i>European Journal of Immunology</i> , 2012, 42, 598-606.	1.6	39
6	Gene therapy for Duchenne muscular dystrophy. <i>Current Opinion in Neurology</i> , 2012, 25, 588-596.	1.8	34
7	DMD transcript imbalance determines dystrophin levels. <i>FASEB Journal</i> , 2013, 27, 4909-4916.	0.2	30
8	A 3-base pair deletion, c.9711_9713del, in DMD results in intellectual disability without muscular dystrophy. <i>European Journal of Human Genetics</i> , 2014, 22, 480-485.	1.4	30
9	The Dynamics of Compound, Transcript, and Protein Effects After Treatment With 2OMePS Antisense Oligonucleotides in mdx Mice. <i>Molecular Therapy - Nucleic Acids</i> , 2014, 3, e148.	2.3	28
10	Dose-Dependent Pharmacokinetic Profiles of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotides in mdx Mice. <i>Nucleic Acid Therapeutics</i> , 2013, 23, 228-237.	2.0	23
11	Assessment of cardiac function in three mouse dystrophinopathies by magnetic resonance imaging. <i>Neuromuscular Disorders</i> , 2012, 22, 418-426.	0.3	19
12	Muscle biopsies in clinical trials for Duchenne muscular dystrophy – Patients™ and caregivers™ perspective. <i>Neuromuscular Disorders</i> , 2019, 29, 576-584.	0.3	17
13	Prednisolone Treatment Does Not Interfere with 2'-O-Methyl Phosphorothioate Antisense-Mediated Exon Skipping in Duchenne Muscular Dystrophy. <i>Human Gene Therapy</i> , 2012, 23, 262-273.	1.4	14
14	Cross-sectional study into age-related pathology of mouse models for limb girdle muscular dystrophy types 2D and 2F. <i>PLoS ONE</i> , 2019, 14, e0220665.	1.1	14
15	Accurate Dystrophin Quantification in Mouse Tissue; Identification of New and Evaluation of Existing Methods. <i>Journal of Neuromuscular Diseases</i> , 2016, 3, 77-90.	1.1	13
16	Influence of full-length dystrophin on brain volumes in mouse models of Duchenne muscular dystrophy. <i>PLoS ONE</i> , 2018, 13, e0194636.	1.1	10
17	Simvastatin Treatment Does Not Ameliorate Muscle Pathophysiology in a Mouse Model for Duchenne Muscular Dystrophy. <i>Journal of Neuromuscular Diseases</i> , 2020, 8, 1-19.	1.1	9
18	Safety issues and harmful pharmacological interactions of nutritional supplements in Duchenne muscular dystrophy: considerations for Standard of Care and emerging virus outbreaks. <i>Pharmacological Research</i> , 2020, 158, 104917.	3.1	9

#	ARTICLE	IF	CITATIONS
19	7â€²,5â€²-alpha-bicyclo-DNA: new chemistry for oligonucleotide exon splicing modulation therapy. <i>Nucleic Acids Research</i> , 2021, 49, 12089-12105.	6.5	6
20	The Effect of 6-Thioguanine on Alternative Splicing and Antisense-Mediated Exon Skipping Treatment for Duchenne Muscular Dystrophy. <i>PLOS Currents</i> , 2012, 4, .	1.4	4
21	Meeting on data sharing for Duchenne 21â€²22 March 2019 Amsterdam, the Netherlands. <i>Neuromuscular Disorders</i> , 2019, 29, 800-810.	0.3	3
22	A modified diet does not ameliorate muscle pathology in a mouse model for Duchenne muscular dystrophy. <i>PLoS ONE</i> , 2019, 14, e0215335.	1.1	2
23	Authorâ€™s Response to: Rebuttal to: Simvastatin Treatment Does Not Ameliorate Muscle Pathophysiology in a Mouse Model for Duchenne Muscular Dystrophy, Verhaart et al. 2020. <i>Journal of Neuromuscular Diseases</i> , 2021, 8, 867-868.	1.1	1